Author

Jan Stöhr

AbbVie (United States)ORCID 0000-0003-2610-7458Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 2 Genetic & Genomic Medicine· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:proteomics· 3 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

Saurabh Khasnavis· 2 shared A. Ouared· 1 shared Akash ModyiD· 1 shared Alban OrdureauiD· 1 shared Alex Laishu· 1 shared Ameya S KulkarniiD· 1 shared Andrea EastesiD· 1 shared Aurélien Davranche· 1 shared

Activity by Year

2023-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Saurabh Khasnavis

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Genetic & Genomic MedicineScientific ReportsPeer-reviewedSep 2, 2026

Progression GWAS followed by functional characterization implicates E3 ubiquitin ligase TRIM2 as a potential genetic modifier of Parkinson's Disease progression

Ameya S Kulkarni, Daniel J. Apicco, Saleh Tamim…·Hyun Ji Noh

The paper performs a GWAS on PD progression metrics and identifies TRIM2 as a genetic modifier, showing its role in regulating neurofilament light and alpha-synuclein aggregation.

DOI 10.1038/s41598-026-67630-7

humanGWAS summary statistics

𝕏 PostBluesky

NeuroscienceNeurobiology of DiseasePeer-reviewedJan 18, 2026

Astrocytic lysosome deficits reduce alpha-synuclein degradation and induce spread of pathology

Lindsay M. Roth, Olga Morozova, Jan Stöhr, Jason Schapansky

This study shows that astrocytic lysosome deficits impair alpha-synuclein degradation and promote its pathological spread in Parkinson's Disease.

5 citationstop 1%

humanproteomics

𝕏 PostBluesky

Systems BiologybioRxivPreprintDec 18, 2023

An approach to characterize mechanisms of action of anti-amyloidogenic compounds in vitro and in situ

Patrick Stalder, T. Serdiuk, Dhiman Ghosh…·Paola Picotti

This paper introduces a structural proteomic pipeline to study anti-amyloidogenic compounds' mechanisms in vitro and in situ, revealing off-target effects and structural interactions with α-Synuclein.

4 citations

humanproteomics

𝕏 PostBluesky

NeurosciencebioRxivPreprintFeb 14, 2023

Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models

R Chin, Rishi Rakhit, Dara Ditsworth…·Nicholas T. Hertz

This study identifies MTK458, a PINK1 activator, which reduces α-synuclein pathology and pUb levels in Parkinson's disease models and correlates plasma pUb with disease progression.

41 citations

humanmouse

𝕏 PostBluesky